TOGETHER,
           WE ARE CHANGING
           THE FUTURE

                                    Avellino, a leader in precision medicine, is making a global impact in genetics

                                    and bringing innovative diagnostics, therapies, and AI-driven data processing to

                                    patient care.

1_AvaGen-Logo-Tag-color

AvaGen is the the first and leading

personalized genetic eye test. AvaGen

quantifies the risk or presence of

keratoconus and other corneal

genetic disorders caused by

gene variants.

AvellinoCov2_logo_final-01

The Avellino SARS-CoV-2/COVID-19

Test (AvellinoCoV2) is a non-invasive,

swab based test used to detect the

SARS-CoV-2 virus.

A global leader in precision medicine,gene therapy, and molecular diagnostics

Our mission is to bring personalized medicine to eyecare

professionals by delivering actionable information derived

from the unique genes of individual patients. 

Collabration help us aim higher

Avellino collaborates with best-in-class partners to create first-in-class

genetic tests and gene-editing therapies. These collaborations

provide the chance to integrate precision medicine into existing

healthcare practices and ultimately improve them.

Transforming data into action

Data must be straightforward for precision medicine to be properly

integrated into clinical care. Avellino provides multiple layers of

support in the patient treatment process to assist the clinician with

interpreting results, explaining results to patients, delivering

personalized treatment, and improving patient outcomes

Precision medicine starting with the eye

At its very core, precision medicine begins with genetics. Tailoring

treatment relies on recognizing individual characteristics and a

patient’s unique susceptibility to certain diseases. For Avellino,

providing real genetic data that correlate with those susceptibilities is

the key.

Where to next?

Avellino is building upon the success of its own proprietary Universal

test, the world’s first DNA test confirming the presence of genetic

indicators positively associated with corneal dystrophies. Our latest

preemptive diagnostic tool, AvaGen, addresses keratoconus in

addition to corneal dystrophies, and is set to expand to address Fuchs’

dystrophy, glaucoma, and a wide range of other eye diseases in the

near future.